An experimental herpes pill taken just once a week has now posted its final early-stage trial results, and they look much like the promising interim numbers people saw last year. At IDWeek 2026 (October 21–24 in Washington, DC), researchers presented final Phase 1b data on GS-1179, an investigational drug from Gilead Sciences, originally developed by Assembly Biosciences, for people with recurrent genital herpes. At the highest dose tested, the HSV-2 shedding rate was 97% lower than with placebo over the study period.

The short version: GS-1179 is a once-weekly oral medicine in the same new drug class as the recently approved pritelivir. In a small, short, placebo-controlled study, it sharply reduced how often the virus showed up on genital swabs and how often sores appeared. It is not approved, it isn't available outside research studies, and larger trials are still needed.

What is GS-1179?

GS-1179 (formerly called ABI-1179) is a helicase-primase inhibitor. It blocks an enzyme complex that herpes simplex virus needs to copy itself. That's a different target from today's standard antivirals, acyclovir, valacyclovir and famciclovir, which work on the virus's polymerase. It was designed as a long-acting pill, so it could potentially be taken once a week instead of every day.

If the drug class sounds familiar, it's because the FDA recently approved pritelivir (Hovilpri), also a helicase-primase inhibitor. Pritelivir is approved for a narrow group: immunocompromised adults whose herpes lesions don't respond to standard treatment. GS-1179 is being studied for a much larger group, people with recurrent genital herpes who want to suppress outbreaks. Its sister compound, now called GS-5366, is the drug we covered in our earlier post on ABI-5366 trial results.

What the final results showed

According to the efficacy poster presented at IDWeek 2026 (P-2052), the randomized, blinded study enrolled 73 adults with HSV-2 who had 4 to 9 genital herpes outbreaks a year. Each person took GS-1179 (50 mg, 20 mg or 10 mg) or a placebo once a week for 29 days and swabbed twice a day so researchers could measure viral shedding. Compared with placebo:

• HSV-2 shedding rate fell by 97% at 50 mg, 91% at 20 mg and 62% at 10 mg.
• High viral load shedding, the level the researchers say is linked to a higher chance of passing the virus to a partner, fell by 100%, 95% and 82%.
• Days with any genital lesion fell by 74%, 82% and 80%.
• Days with lesions confirmed to contain HSV-2 fell by 92%, 100% and 83%.
• Shedding episodes were shorter: an average of 0.5 days at the top dose versus 4.1 days with placebo.

The authors describe these results as "nominally statistically significant," a careful way of saying the differences were clear in this small study but weren't designed to prove effectiveness on their own. In December 2025, Assembly Biosciences had reported interim results showing a 98% shedding reduction at the 50 mg dose. The final number, 97%, is close to that.

What about side effects?

The companion safety poster (P-2059) reports that most side effects were mild or moderate (Grade 1 or 2). Headache was the most common side effect considered related to the drug, reported by 30%, 10% and 22% of people in the 50, 20 and 10 mg groups, compared with none on placebo. Most of those headaches went away by the end of follow-up. No one stopped treatment early because of a side effect, and there were no deaths. One person in the 10 mg group had serious abdominal pain that investigators judged was not related to the drug.

Important limits to keep in mind

• It's early. This was a Phase 1b study of 72 evaluated people over about a month. Larger, longer trials have to confirm both benefit and safety.
• Transmission wasn't measured directly. Less shedding is expected to mean less risk to partners, but this study didn't follow couples.
• People with HIV were excluded. The study didn't include people living with HIV or hepatitis B or C, so we don't yet know how the drug works for them.
• Participants weren't very diverse. Most people in each group were white.
• There's no head-to-head comparison with valacyclovir or other standard antivirals in this study.

What happens next

Gilead has licensed the program from Assembly Biosciences. According to Assembly's pipeline page, Gilead "has elected to advance GS-1179 into a Phase 2 study" in people with recurrent genital herpes. No approval timeline has been announced. Any approval would depend on larger trials and FDA review.

What this means for dating with herpes

For many people with herpes, the hardest part isn't the outbreaks. It's worrying about a partner. Results like these matter because they point to a future with more options and possibly less day-to-day hassle. For now, here's what holds true:

• Effective options already exist. Daily suppressive therapy can reduce outbreaks, and valacyclovir is FDA-approved to help lower the risk of passing genital herpes to a partner when used along with safer-sex practices. Don't stop or change a medicine while waiting for a new one; talk with your clinician first.
• Shedding without symptoms is normal. It's a big reason herpes spreads. Our explainer on asymptomatic herpes explains why, and why it's nothing to be ashamed of.
• Honest conversations still matter. Talking about status, condoms and medicine helps partners make choices together. Disclosure expectations and legal duties differ by state, so check the rules where you live.
• Date safely. Meet new matches in public, verify who you're talking to, and make sure everything is consensual.

Quick FAQ

Can I get GS-1179 now?

No. It's investigational and only available in clinical trials. Be wary of any website selling "herpes cures." In an October 1, 2026 warning letter, the FDA said it "has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI."

Is GS-1179 a cure?

No. It's being developed to suppress outbreaks and shedding, not to remove the virus from the body.

The bottom line

A weekly pill that cuts herpes shedding by more than 90% would be a real step forward, and these final early results keep that possibility alive. It's still early, and today's treatments already help. Whatever comes next, herpes doesn't have to stand between you and a good relationship. If you're ready to meet people who get it, explore herpes dating on MeetPositives.

Sources

• Edwards A, et al. "Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study." Poster P-2052, IDWeek 2026, October 21–24, 2026.
• Edwards A, et al. "Safety and Tolerability of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study." Poster P-2059, IDWeek 2026.
• Assembly Biosciences, Pipeline: GS-1179 and GS-5366, accessed October 27, 2026.
• Assembly Biosciences, interim Phase 1b results news release, December 8, 2025.
• ClinicalTrials.gov, NCT06698575.
• US Food and Drug Administration, warning letter to Amazon.com, Inc. (MARCS-CMS 736006), October 1, 2026.

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney.